Similar findings were observed when considering only patients with hormone receptor-negative, HER2-positive tumours (488 of 572) or hormone receptor-positive, HER2-positive tumours (756 of 858) who received neoadjuvant HER2-targeted therapies with neoadjuvant chemotherapy (appendix pp 5–6). Here, ERBB2 is linked to neoplasm.